[Multistain deep learning as a prognostic and predictive biomarker in colorectal cancer].

Abstract

The tumor immune microenvironment (TIME) plays acrucial prognostic and predictive role in solid malignancies such as colorectal cancer (CRC). Nevertheless, scoring systems based on TIME such as the Immunoscore (IS) are rarely used in clinical practice. Among other reasons, this might be due to the additional time required for manual quantification of tumor-associated immune cells or costs associated with proprietary/commercial solutions. To address these issues, we developed amultistain deep learning model (MSDLM) and trained, validated, and tested it on immunohistochemical image data of different immune cell subtypes from over 1000 patients with CRC. Our model showed high prognostic accuracy and outperformed other clinical, molecular, and immune cell-based parameters. It might also be used for therapy response prediction in rectal cancer patients undergoing neoadjuvant therapy. Leveraging artificial intelligence interpretability/explainability methods, we ascertained that the MSDLM's predictions align with recognized antitumor immune response patterns. Consequently, the AImmunoscore (AIS) could emerge as apotential TIME-based decision-making tool for clinicians.